Entering text into the input field will update the search result below

Oncternal Therapeutics announces agreement with FDA on phase 3 trial for zilovertamab

Jan. 04, 2022 4:27 PM ETONCTBy: Jessica Kuruthukulangara, SA News Editor
  • Oncternal Therapeutics (NASDAQ:ONCT) announces agreement with FDA on phase 3 registrational study design for zilovertamab in the treatment of mantle cell lymphoma (MCL).
  • The FDA also provided positive feedback on the proposed clinical and regulatory requirements of the development program

Recommended For You

More Trending News